Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAXV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics, Inc. became an independent, publicly traded biotech company through a spin-off from AnaptysBio, with AnaptysBio shareholders receiving one First Tracks share for each AnaptysBio share held on the April 6, 2026 record date. The company simultaneously closed a private placement in which it issued 5,791,478 shares of common stock and EcoR1 Capital Fund Qualified, L.P. sold 4,705,575 of its spin-off shares to investors at $13.81 per share. A Separation and Distribution Agreement and a Transition Services Agreement allocate assets, liabilities, services and IP between AnaptysBio and First Tracks and govern post-spin relations. The company also adopted non-employee director cash and equity compensation programs and appointed Ajim Tamboli as Chief Financial Officer with a $516,000 base salary, target bonus opportunity and equity awards valued at $2,550,000. First Tracks’ lead programs include ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis and ANB101 in early-stage development, and its stock began trading on Nasdaq under the symbol TRAX.
First Tracks Biotherapeutics, Inc. outlines its planned separation from AnaptysBio through a taxable spin-off and concurrent private financing. AnaptysBio stockholders of record on April 6, 2026 will receive one First Tracks share for each AnaptysBio share when the distribution occurs on April 20, 2026.
First Tracks shares are expected to trade on Nasdaq under the symbol “TRAX”, with when-issued trading under “TRAXV” beginning April 6, 2026. A private placement will sell 5,791,478 new shares at $13.81 per share, targeting about $80 million in gross proceeds to fund the company’s clinical-stage immunology pipeline.
First Tracks Biotherapeutics, Inc. director Rita Jain filed an initial Form 3, formally registering as an insider of the company. The filing reports no transactions, no derivative activity, and no specific share holdings at this time.